Firm News
Wiggin and Dana Advises Client Rallybio in its Collaboration with AI Drug Discovery Company, Exscientia
On behalf of the Firm, Wiggin and Dana Partners Peter Gruen, Evan Kipperman and Patti Melick and Associate R.J. Kornhaas represented client Rallybio, LLC in its collaboration with artificial intelligence (AI) drug discovery company Exscientia to form a joint venture – called RE Ventures – that uses AI to accelerate discovery of small molecule drug candidates for undisclosed rare disease indications.
To learn more, please click here.
